Gene based therapy for sickle cell disease in low and middle income countries insights from the Gambia

Article summary

Sickle Cell Disease (SCD) poses a significant health challenge in low- and middle-income countries, particularly in sub-Saharan Africa, where access to effective treatments is severely limited. This review highlights the potential of gene-based therapies, such as CRISPR-Cas9 and lentiviral treatments, while emphasizing the urgent need for sustainable financing and healthcare infrastructure improvements to ensure equitable access and effective implementation in resource-constrained settings like The Gambia.